Abstract
Cystatin C (CysC) has been used as a renal function indicator and a strong predictor of cardiovascular events. In this study, we determined the prognostic value of serum CysC in patients with acute ischemic stroke (AIS) and examined its protective role on ischemic brain injury. First-ever stroke patients (601 cases) and control subjects (325 cases) were recruited. Serum CysC level in patients with AIS were significantly higher than that in controls. Multivariate logistic regression analyses showed that elevated CysC is an independent risk factor of AIS; the odds ratio (95 % confidence interval) was 9.80 (3.12–30.83). The integrated population was divided into quintiles according to serum CysC. Compared with the first quintile, the odds ratios of risk for AIS in fourth quintile and fifth quintile were 1.92 (1.08–3.40) and 2.88 (1.49–5.54), respectively. Serum CysC was not associated with neurological deficits and the location of ischemic area; however, serum CysC in patients decreased after one-week therapy. This was consistent with CysC expression after ischemia/reperfusion injury in a mouse focal ischemia/reperfusion injury model. Exogenous CysC exerted neuroprotective effects by reducing infarct volume in this animal stroke model. Therefore, serum CysC is highly associated with AIS and is an independent prediction marker for AIS. Since our findings demonstrated the protection of exogenous CysC on ischemic brain injury, CysC is a novel and promising therapeutic target for AIS.
This is a preview of subscription content, log in via an institution to check access.
References
Angelidis C, Deftereos S, Giannopoulos G, Anatoliotakis N, Bouras G, Hatzis G, Panagopoulou V, Pyrgakis V, Cleman MW (2013) Cystatin C: an emerging biomarker in cardiovascular disease. Curr Top Med Chem 13(2):164–179
Chen J, Sun M, Zhang X, Miao Z, Chua BH, Hamdy RC, Zhang QG, Liu CF, Xu X (2015) Increased oligodendrogenesis by humanin promotes axonal remyelination and neurological recovery in hypoxic/ischemic brains. Hippocampus 25(1):62–71
Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40(2):221–226
Frankel MR, Morgenstern LB, Kwiatkowski T, Lu M, Tilley BC, Broderick JP, Libman R, Levine SR, Brott T (2000) Predicting prognosis after stroke: a placebo group analysis from the national institute of neurological disorders and stroke rt-PA stroke trial. Neurology 55(7):952–959
Gauthier S, Kaur G, Mi W, Tizon B, Levy E (2011) Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci 3:541–554
Hakansson K, Huh C, Grubb A, Karlsson S, Abrahamson M (1996) Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp Biochem Physiol B 114(3):303–311
Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzheimers Dis 16(2):389–397
Hsieh FI, Chiou HY (2014) Stroke: morbidity, risk factors, and care in taiwan. J Stroke 16(2):59–64
Ishimaru H, Ishikawa K, Ohe Y, Takahashi A, Maruyama Y (1996) Cystatin C and apolipoprotein E immunoreactivities in CA1 neurons in ischemic gerbil hippocampus. Brain Res 709(2):155–162
Kaur G, Levy E (2012) Cystatin C in Alzheimer’s disease. Front Mol Neurosci 5:79
Lisak M, Demarin V, Trkanjec Z, Basic-Kes V (2013) Hypertriglyceridemia as a possible independent risk factor for stroke. Acta Clin Croat 52(4):458–463
Ni L, Lu J, Hou LB, Yan JT, Fan Q, Hui R, Cianflone K, Wang W, Wang DW (2007) Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 38(12):3287–3288
Olsson T, Nygren J, Hakansson K, Lundblad C, Grubb A, Smith ML, Wieloch T (2004) Gene deletion of cystatin C aggravates brain damage following focal ischemia but mitigates the neuronal injury after global ischemia in the mouse. Neuroscience 128(1):65–71
Palm DE, Knuckey NW, Primiano MJ, Spangenberger AG, Johanson CE (1995) Cystatin C, a protease inhibitor, in degenerating rat hippocampal neurons following transient forebrain ischemia. Brain Res 691(1–2):1–8
Pirttila TJ, Pitkanen A (2006) Cystatin C expression is increased in the hippocampus following photothrombotic stroke in rat. Neurosci Lett 395(2):108–113
Seyfried D, Han Y, Zheng Z, Day N, Moin K, Rempel S, Sloane B, Chopp M (1997) Cathepsin B and middle cerebral artery occlusion in the rat. J Neurosurg 87(5):716–723
Tong DC, Yenari MA, Albers GW, O’Brien M, Marks MP, Moseley ME (1998) Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 hour) ischemic stroke. Neurology 50(4):864–870
Xiao D, Liu H, Zhang H, Luo Y (2012) Impact of cystatin C levels on infarct size and hemorrhage volume in acute cerebral stroke. J Neurol 259(10):2053–2059
Xu L, Sheng J, Tang Z, Wu X, Yu Y, Guo H, Shen Y, Zhou C, Paraoan L, Zhou J (2005) Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies. Neurobiol Dis 18(1):152–165
Xu XS, Chua CC, Gao JP, Hamdy RC, Chua BHL (2006) Humanin is a novel neuroprotective agent against stroke. Stroke 37(10):2613–2619
Acknowledgments
This study was supported by the grants from the National Natural Science Foundation of China (81071095, 81120108011, and 81361128010) and the Priority Academic Program Development of Jiangsu Higher Education Institutions of China. The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Bo Yang and Jiangtao Zhu were co-first authors.
Rights and permissions
About this article
Cite this article
Yang, B., Zhu, J., Miao, Z. et al. Cystatin C is an Independent Risk Factor and Therapeutic Target for Acute Ischemic Stroke. Neurotox Res 28, 1–7 (2015). https://doi.org/10.1007/s12640-015-9522-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-015-9522-3